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Abstract Transcriptome analysis is a powerful tool for
evaluating molecular pathways central to maturation of
specific biological processes and disease states. Recently,
PCR-based arrays have supplemented microarray and
RNA-seq methodologies for studying changes in gene
expression levels. PCR arrays are a more cost efficient
alternative, however commercially available assemblies are
generally limited to only a few more widely researched
species (e.g., rat, human, and mouse). Consequently, the
investigation of emerging or under-studied species is hin-
dered until such assays are created. To address this need,
we present data documenting the success of a developed
workflow with enhanced potential to create and validate
novel RT-PCR arrays for underrepresented species with
whole or partial genome annotation. Utilizing this
enhanced workflow, we have achieved a success rate of
80 % for first-round designs for over 400 primer pairs. Of
these, *160 distinct targets were sequence confirmed.
Proof of concept studies using two unique arrays, one
targeting the pathogenic bacterium Mycoplasma genitalium
and the other specific for the guinea pig (Cavia porcellus),
allowed us to identify significant (P \ 0.05) changes in
mRNA expression validated by subsequent qPCR. This
flexible and adaptable platform provides a valuable and
cost-effective alternative for gene expression analysis.
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Introduction
For many novel emerging or under-studied organisms, the
lack of assays to quantify and characterize proteins and
phenotype necessitates the evaluation of nucleic acids.
While partial or complete genomic sequence may be
available for many of these organisms, the expertise and
cost required for de novo sequencing or to develop assays
for measuring transcription level changes can be a signif-
icant deterrent to the development of custom in-house
reagents. The lack of demand for niche products to address
under-studied or emerging organisms further diminishes
the likelihood of commercial production of reagents.
Transcriptional analysis can yield important information
about expression patterns for developmental processes,
evolving gene regulation, and for highlighting differences
between healthy and diseased states [1]. For the last few
decades, gene expression analysis has been dominated by
the use of microarrays. Recently, new approaches using
next-generation sequencing (NGS) have led to the devel-
opment of improved transcriptomic techniques such as
RNA-seq [2, 3]. However, transcriptome analysis by either
microarray or RNA-seq is currently widely utilized in a
discovery role for large-scale gene expression studies [3]
and transcript-level analyses made possible by both tech-
nologies have revolutionized molecular biology [2, 4].
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Microarrays are especially useful to explore gene expres-
sion of multiple cellular pathways in parallel and these
assays are widely available for a number of model organ-
isms [3]. The newer RNA-seq technologies can also fill this
role and additionally offer lower background signal over
microarray techniques [3]. Coupled with the detection of
transcripts that may be at very high or very low abundance
levels [3], RNA-seq is quickly displacing microarrays as
the preferential tool for gene expression analysis [5, 6].
While these methods have undoubtedly increased our
understanding of transcriptomics, they require specialized
equipment and expensive reagents, particularly with
respect to RNA-seq, leading to increased costs per sample
interrogated. While advances to these technologies have
substantially reduced costs in recent years, a 20 million
read RNA-seq reaction can be *$1,000USD/sample
increasing to nearly $3,000USD/sample for de novo
sequencing (personal communication and web search). An
additional concern surrounding RNA-seq is the introduc-
tion of bias at many steps during the process associated
with technical inexperience, leading to unwanted variation
across samples [1, 5, 7, 8].
Real-time reverse transcription PCR (RT-PCR) has been
a widely used methodology for detecting transcriptional
changes in mRNA [9, 10], and is the preferred method for
validating both microarray and RNA-seq gene expression
studies [3, 11]. Recently, this technique has been used to
create PCR arrays for use in high-throughput gene profil-
ing. These arrays combine ease of use, reliability, and
reproducibility of RT-PCR into a more cost-effective
method for screening large numbers of genes simulta-
neously [3] and so provide an attractive alternative to
microarray or NGS methodologies. However, their utility is
currently limited due to the availability of arrays for only a
few of the more widely used research species. The
restricted number of genes that may be analyzed simulta-
neously also presents another disadvantage to this meth-
odology [3].
Optimal screening of broad transcriptional changes by
RT-PCR requires a design approach that allows for up to
96 targets to be processed through a single set of PCR
parameters. PCR primer design has been described previ-
ously for single target and multiplex designs [12] but
required some enhancement to address the needs created by
the transcriptional array. Our goal was to create a highly
adaptable and cost-effective workflow with enhanced pri-
mer design, a broadly useful PCR program and algorithms
for data analysis to facilitate gene expression analysis in
under-studied organisms. As a result, we present a flexible
PCR array development and validation method that creates
adaptable screening tools to study changes in the tran-
scriptome of any species with adequate genomic sequence.
As proof of concept, we present the successful
development and validation of two disparate arrays tar-
geting the bacterial pathogen Mycoplasma genitalium
(MG) and the commonly utilized guinea pig (Cavia por-
cellus), both of which currently lack commercially avail-
able assays for transcriptome analysis.
Materials and Methods
Optimized Thermocycling Protocol
To identify a thermocycling protocol central to the func-
tionality of our array platform, we first tested four estab-
lished protocols using primer pairs from our first-
generation designs. These first evaluations targeted RNA
species produced by the sexually transmitted bacterial
pathogen MG. Specifically, type strain MG G37 genomic
sequence (GenBank Accession: L43967) was used as a
template to design 11 sets of forward and reverse primers
for highly conserved genes within the bacterium using
generic primer selection parameters. Each primer pair was
used to amplify three distinct concentrations of purified
MG genomic DNA covering a range of 105–107 copies per
reaction. The resulting quantification cycle (Cq) values
[12], generated during SYBR green-based real-time PCR
amplification, provided the opportunity to calculate the
amplification efficiency of the 11 primer pairs using each
of the four PCR thermocycling protocols. These pre-
liminary studies identified a protocol that produced the
most consistent PCR efficiencies across the 11 primer
pairs. In addition, a melt temperature (Tm) analysis was
performed to provide information on the identity of the
amplimer created in each reaction.
The optimal protocol identified by this initial evaluation
was repeatedly modified by empirical testing of additional
primer pairs to refine the thermocycling conditions. This
resulted in a stable set of parameters to serve as the fun-
damental PCR protocol for our array system. The resultant
protocol, designated as ‘‘KS’’, was established as our
standard and subsequently used to evaluate and refine
primer design methods to maximize successful targeting of
selected genes.
Primer Design and Optimization
Primers were designed using Beacon Designer v7.91
(PREMIER Biosoft; Palo Alto, CA, USA) and regions of
each gene were selected by prescreening to identify areas
that were highly conserved based on alignments of all
available sequences. Initial observations from data
obtained during our thermocycling protocol validation
studies suggested that primers composed of less than 40 %
guanine/cytosine (G/C) content were more efficient with
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the optimized KS protocol, a finding that was confirmed
through subsequent primer design and testing studies.
Thus, for maximum compatibility with the array platform,
the optimal primer should incorporate B40 % G/C content.
Our results also correlated PCR amplimer length with
overall primer efficiency success rates. The data from
almost 200 primer pairs led us to conclude that optimal
amplimer length should be between 70 and 200 base pairs
(bp) and led to the primer design specifications described
below. All subsequent primer design was undertaken using
these parameters.
Forward and reverse oligonucleotide primers were
designed with custom settings in Beacon Designer v7.91.
Previously reported primer design approaches [12] pro-
vided the basis for the initial parameters that were then
empirically optimized. Primer length was 18–24 nucleo-
tides and PCR amplimers were selected to be between 70
Fig. 1 Generalized workflow for primer validation. Primers first met
PCR efficiency criteria (80–120 %). Secondary evaluation of target
specificity used high resolution melt temperature analysis to confirm
the presence of a single melt peak. Final confirmation of primer
specificity utilized electrophoresis through agarose to ensure only one
product was produced, validating the primer pair, and establishing the
expected Tm for each corresponding amplimer. Approximately 40 %
of all amplimers were sequenced with 100 % confirmation of their
identities
Fig. 2 Secondary primer pair validation was conducted by melt
temperature (Tm) analysis to confirm target specificity. All reactions
were carried out as three, 10-fold dilutions analyzed in duplicate. a A
single melt peak indicated production of one product and a passed
secondary evaluation. b Multiple melt peaks were indicative of off-
target primer binding or primer-dimer formation, resulting in multiple
amplification products. The lower panel primer pair did not pass
validation and was re-designed. c An example of a primer pair that
produced a primer-dimer in the no template control well. This primer
pair passed validation as the Tm of the primer-dimer was C5 C from
the expected Tm. All panels: the dotted line indicates the baseline
threshold
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and 200 bp with primers designed to contain B40 % GC
where possible. Primers were purchased as desalting-puri-
fied lyophilized material from Sigma-Aldrich (St. Louis,
MO) and reconstituted with sterile Tris–EDTA (TE) buffer
(10 mM Tris–HCl, 1 mM EDTA Na2, pH 8.0, Promega,
Madison, WI) to a concentration of 500 lM. Aliquots of
each forward and reverse primer were made by dilution to a
concentration of 5 lM in TE buffer. All primer stocks were
stored frozen at -20 C until plated for array assembly.
Genomic sequence for the guinea pig (Cavia porcellus)
was downloaded from the Ensembl database (http://useast.
ensembl.org/Cavia_porcellus/Info/Index); sequence for
MG (prototypic laboratory strain G37) was obtained from
GenBank (http://www.ncbi.nlm.nih.gov/genbank/).
Primer Validation
Primer pair candidates were required to pass two validation
criteria before being considered for inclusion onto an array
assembly. A generalized flow chart of this primer pair
validation process is shown in Fig. 1.
Equivalent PCR efficiency is an essential aspect to the
effective development of a multi-target system to be used
on one sample to produce semi-quantitative data. Based
upon extensive experience in designing and implementing
quantitative PCR (qPCR) assays [13–18], efficiencies
between 80 and 120 % with associated correlation coeffi-
cients C0.95 are required to provide optimal data for
comparing transcription levels of selected genes within a
sample and to ensure correct normalization across com-
parator samples. To determine the PCR efficiencies of
newly designed primer pairs, a PCR master mix was made
(‘‘PCR’’ section) for each primer pair set and a series of
three, and 10-fold dilutions of DNA (for MG primers) or
cDNA (for Cavia porcellus primers) were prepared and
used as the template for the PCR. This series of dilutions
served as a calibration curve that provided an accurate
assessment of efficiency for each putative gene target.
Additionally, a negative template control (NTC) was
included on all validation runs to identify primer pairs that
formed primer-dimers in reactions with little or no target
sequence. Amplification of a primer pair that results in a
PCR product from primer-dimer formation may still be
considered for inclusion on an array build provided that the
Tm obtained varies by at least 5 C from the Tm of the
expected product (Fig. 2c). If a primer pair results in a PCR
efficiency of 80–120 %, primer pair specificity is next
confirmed to ensure the fidelity of the reaction.
Primer specificity was a second and equally important
consideration during the validation process. Confirmation
of the identity of each amplimer was completed by melt
temperature analysis at the end of the amplification cycles
to create a specific Tm for each of the amplified products. A
single Tm suggested that only one PCR product was pro-
duced. In cases of single Tm (Fig. 2a), agarose gel elec-
trophoresis confirmed the product size. Successful
amplification was indicated by a single band that corre-
sponded to the predicted amplimer size. During optimiza-
tion, if multiple Tms (Fig. 2b) or a band of unexpected size
was observed, the primer pair was considered sub-optimal,
and was subjected to re-design and re-validation. Sanger
sequencing of randomly selected PCR products (to date
approximately 40 % of the total targets) showed 100 %
specificity and was achieved using our validation approach.
The Tm established for each successful primer pair was
used as a subsequent quality control evaluation for exper-
imental runs prior to analyses of gene expression differ-
ences. This workflow, using the optimized KS protocol and
refined PCR primer pair design parameters, created an
overall success rate of 80 % for over 400 first-round primer
pairs tested to date. Second round re-design led to success
for the majority of the targets, although 5 % required a
third round of design, suggesting that a small subset of
target genes may fail our array approach.
Assembly of Array Plates
Validated optimized primer pairs were robotically plated
into 96-well skirted PCR plates. Use of a 12-channel pipet
for distribution of primers to array plates was confirmed to
be a viable, although laborious, alternative to robotic
plating. After array plating, multiple array plates were
chosen at random and tested to address quality and con-
tamination concerns. Water only control PCR confirmed
that no contamination occurred during the plating process.
Assembled array plates were tested using target nucleic
acid to confirm primer activity conformed to results
obtained during optimization and validation studies.
For the guinea pig, host immune response transcription
array (gpArray), two additional quality controls were
conducted after array plates were produced. Purified Vero
and human DNA were tested in the gpArray to determine if
the guinea pig primer pairs would recognize homologies in
those genomes. These DNAs were specifically selected to
identify possible sources of contamination that could be
introduced at the time of sampling or during downstream
sample manipulation: human DNA from laboratory per-
sonnel collecting and preparing the samples, and Vero cell
DNA to control for extraneous genetic material present in
virus stocks grown in Vero cells and introduced during
inoculation of test animals. Interestingly, both Vero and
human DNA were recognized by the guinea pig primers
(data not shown) and resulted in successful amplification of
gene targets. Melt temperature analysis of the corre-
sponding PCR amplimers showed that 82 % of the result-
ing Vero Tms and 85 % of the human Tms were sufficiently
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different (±0.8 C) to be distinguished by our standard
quality assessment prior to data analysis. Of those targets
that were B0.8 C, only 7 Vero and 7 human DNA am-
plimers produced Tms that were indistinguishable from
their guinea pig counterparts.
RNA Extraction and cDNA Synthesis
Template RNAs were extracted using the Aurum Total
RNA 96 kit (Bio-Rad) following the manufacturer’s
instructions and included an on-column DNase I digestion
to remove genomic DNA contamination. Prior to reverse
transcription of the RNA using the iScript cDNA Synthesis
kit (Bio-Rad), lack of DNA contamination was confirmed
using a Taqman qPCR targeting the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
cDNA synthesis reactions were carried out in a final vol-
ume of 60 ll per sample and contained the following
reaction components: 12 ll 5x iScript Reaction Mix, 3 ll
iScript Reverse Transcriptase (225 units), and 45 ll tem-
plate RNA (*600 ng). cDNA synthesis was carried out
using a three-step PCR protocol of 25 C for 5 min fol-
lowed by 30 min at 42 C and a final 5 min incubation at
85 C to stop the reaction. Resulting cDNAs were stored
frozen at -20 C until assayed.
Production of Arrays
For array plating, a fresh 1 ml primer stock containing both
forward and reverse primers for each gene target was
prepared in a sterile 1.8 mL cryovial at a final concentra-
tion of 434.8 nM in TE. This concentration of primer stock
was used to ensure a final 0.2 lM concentration for both
forward and reverse primers upon addition of reaction mix
(see next section ‘‘PCR’’) to all wells of the array plate.
The aliquots were stored on ice until primer mixes were
produced for all targets on a given array. The cryotubes
were briefly centrifuged (300 RCF, *30 s) before being
pipetted into 96-well skirted PCR plates (Thermo Fisher
Scientific, Waltham, MA) at a volume of 11.5 ll per well
using sterile RNase/DNase-free filter tips (Mettler-Toledo,
Columbus, OH). Initial plating was accomplished using a
12-channel pipet (Mettler-Toledo), however subsequent
plating utilized a Tecan Evo 200 robotics platform (Tecan
US, Inc., Morrisville, NC) to increase the throughput,
efficiency, and accuracy of primer distribution. Finished
array plates were covered with sterile foil sealing tape
(Thermo Fisher Scientific) and centrifuged briefly (300
RCF, *30 s) to collect the liquid in the bottom of the
wells. Array plates were stably archived at -20 C for
long-term storage until used for sample screening. Vali-
dated gpArray and MG Array plates can be obtained from
our lab group under MTA or through collaboration.
PCR
All PCR array reactions were completed in 96-well plates
in a total volume of 25 ll. Prior to assembling the reaction
mix, template cDNA was diluted 1:5 in sterile DNase/
RNase-free water. The final volume for the PCR and
dilution of starting material is a best practice suggestion
based on our experience with PCR development [13–18].
The final reaction volume and/or cDNA dilution may be
adjusted as determined by the end user through experi-
mental in-house validation. The reaction mix was assem-
bled using 12.5 ll of 29 iQ SYBR Green Supermix
(Bio-Rad) and 1 ll of diluted cDNA for each well to be
tested. A volume of 13.5 ll of the SYBR-cDNA reaction
mix was then added to each well of an assembled array
plate containing primers (0.2 lM final primer concentra-
tion) using a 12-channel pipet and low retention, RNase/
DNase-free, filtered pipet tips (Mettler-Toledo). Plates
were then sealed with optical tape and briefly centrifuged
(6000 RCF, *30 s) to collect the liquid at the bottom of
the wells prior to PCR. Reactions were carried out on either
CFX or CFX Connect Real-Time PCR detection systems
(Bio-Rad) using the optimized KS protocol consisting of an
8 cycle amplification of 95 C for 30 s, 48 C for 30 s, and
72 C for 30 s followed by a 40 cycle amplification of
95 C for 15 s, 56 C for 20 s, and 72 C for 20 s during
which real-time data were acquired at the annealing step.
Cq analysis was completed by the Bio-Rad CFX Manager
software with a constant baseline adjustment to 50 relative
fluorescent units for all array runs to provide for accurate
comparisons of Cq values across gene targets.
A high resolution melt temperature analysis was inclu-
ded in the thermocycling program following the second
amplification step. Starting at 65 C, the temperature was
raised incrementally by 0.2 C every 5 s, followed by data
acquisition to an ending temperature of 95 C. Tm values
for all amplicons were evaluated by comparing each cor-
responding Tm to established historical values with an
acceptable range of ±0.8 C prior to data analysis.
Reference genes were needed to ensure reliable nor-
malization across samples. However, the expression of
many widely used reference genes can vary due to the
tissue or cell type from which the sample is collected [10].
It has been shown that multiple reference genes should be
used for normalization to avoid unintentional biasing of the
results [19]. Thus, for all array runs, gene expression levels
were normalized using the mean of four reference genes
included on each plate using DDCq [19, 20]. Fold change
was calculated by the normalized gene expression of the
test sample divided by the normalized gene expression of
the control sample. Values greater than one represented an
up-regulation and were considered equal to the fold
change. Fold change values less than one were
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down-regulation and were represented by the negative
inverse of the fold change.
Cloning of PCR Amplimers
Selected PCR amplimers (*40 % of targets) of the proper
size created by initial array runs were purified (QIAquick
PCR Purification kit; Qiagen, Valencia, CA) and then
cloned using the TOPO TA Cloning kit (Life Technologies,
Carlsbad, CA). Selected clones that were within 0.2 C of
their corresponding control were sequenced using an ABI
Prism 3130XL Genetic Analyzer (Carlsbad, CA). Positive
clones were also used to confirm Tm values and were
archived for use in future single target qPCR assays.
qPCR Validation of Array Results
Each qPCR mix contained 1X iQ SYBR Green Supermix,
0.2 lM of each forward and reverse primer, and 1 ll
template cDNA. Cloned amplimers for each gene target
were included on each plate as a series of 10-fold dilutions
(106–102) as quantitation standards to provide a means of
calculating the quantities of each target gene. Two addi-
tional qPCRs were conducted in parallel using the house-
keeping genes hypoxanthine phosphoribosyltransferase 1
(HPRT1) and beta actin to control for cDNA quality and
quantity. Negative template controls were included to
ensure PCR integrity and indicate potential contamination.
All reaction efficiencies were between 80 and 120 % with
correlation coefficients of [0.95. Assay sensitivity for
these reactions allowed for 100 copies to be detected
100 % of the time. Tm analysis was used to confirm primer
specificity and amplimer identity as described above.
Target gene expression levels were normalized using the
geometric mean of the housekeeping genes HPRT1 and
beta actin prior to analyses. The mean of normalized test
sample values for each target gene were divided by nor-
malized control sample values to indicate the fold change
for comparisons to array results. Values greater than one
represented an up-regulation and were considered equal to
the fold change. Fold change values less than one were
down-regulation and were represented by the negative
inverse of the fold change.
Guinea Pig Splenocyte Cell Culture
Female Hartley guinea pigs (250–350 g) were obtained
from Charles River Breeding Laboratories (Wilmington,
MA) and housed in American Association for the
Accreditation of Laboratory Animal Care-certified facili-
ties. Animal studies were approved by the Institutional
Animal Care and Use Committee (IACUC) at the Uni-
versity of Texas Medical Branch (UTMB), and all animals
were humanely euthanized following UTMB IACUC-
approved procedures. Guinea pig spleens were then har-
vested using sterile technique and placed into Hank’s
Balanced Salt Solution (HBSS; Corning Life Sciences-
Mediatech, Inc., Manassas, VA) supplemented with 5 %
(vol/vol) newborn calf serum (Life Technologies Incorpo-
rated, Carlsbad, CA) and 1 % penicillin/streptomycin
(10,000 U/ml penicillin/10,000 lg/ml streptomycin stock;
Sigma-Aldrich). All manipulations of the tissues were
conducted at room temperature. Spleens were minced and
pushed through a metal mesh sieve to produce single-cell
suspensions as described previously [21]. Cells were pel-
leted and washed with HBSS a total of 3 times. Erythro-
cytes were lysed by exposure to acetic acid prior to
splenocyte enumeration. Cells (1 9 106 cells/well) were
seeded into 24-well plates in medium containing RPMI
1640 (Corning Life Sciences-Mediatech, Inc.), 10 %
(vol/vol) fetal bovine serum (FBS; Corning Life Sciences-
Mediatech, Inc.), 1 % penicillin/streptomycin, 1 % L-gluta-
mine (Sigma-Aldrich), 1 % sodium pyruvate (Sigma-Aldrich),
1 % non-essential amino acids (Sigma-Aldrich), and 50 lM b-
mercaptoethanol (Sigma-Aldrich). Half of the wells were fur-
ther supplemented with 50 ng/ml phorbol 12-myristate
13-acetate (PMA) and 1 mM ionomycin to stimulate the cells.
Cells were incubated (37 C, 5 % CO2) for 24 h and then
re-suspended in 0.2 ml Aurum Total RNA Lysis Solution (Bio-
Rad, Hercules, CA) containing 1 % BME, vortexed and stored
at -80 C until used for RNA isolation and cDNA preparation.
Statistical Analysis
Comparisons to detect significant variations in expression
for each target gene were carried out using a two-tailed
Student’s t test after 2-DCq conversion of individual Cq
data to a linear form [20]. Comparisons between gene
expression levels from qPCR assays were made using a
two-tailed Student’s t test after log conversion of the qPCR
results for each target with Prism software (v6.0; Graph-
Pad, La Jolla, CA). For all comparisons, a P value of 0.05
was used to designate significance.
Results
Development of the RT-PCR arrays first required the
selection and optimization of a permissive thermocycling
protocol that would allow multiple diverse primer pairs of
differing annealing temperatures to amplify targets with
similar PCR efficiencies. After optimizing a PCR thermo-
cycling protocol, we refined sequence target selection
parameters to create an optimal primer design paradigm
that increased the success rate for selecting array-
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compatible primer pairs. Additionally, we established tar-
get quality control and validation methodologies to ensure
adequate PCR efficiency and to confirm primer specificity.
Finally, using optimized methods two disparate example
array assemblies were completed and tested to confirm the
flexibility and utility of our approach.
Assembled Transcription Arrays
Several genetically distinct target sets have been success-
fully evaluated using our optimized array design and
assembly methods. As proof of concept, we offer results for
two distinct types of biological target sets with disparate
goals and outcomes.
MG Array Our initial efforts to develop an array plat-
form were driven by our research into the under-studied
bacterial pathogen MG [16, 22]. This bacterium is
responsible for genital tract infection and can develop an
intracellular niche leading to persistent colonization of an
infected individual [23]. MG provides a unique opportunity
for studying the genes associated with infection and the
establishment of persistence as it contains one of the
smallest genomes capable of self-replication. To better
understand the pathogenesis of this bacterium, we designed
primers to target 188 conserved genes representing *40 %
of the known genes of this organism. Using the optimized
workflow, the success rate for first-round primer design
was 83 % with an 80 % success rate for the re-design of
suboptimal primer pairs.
The assembled two 96-well plated array (Supplementary
Table S1) was utilized to study transcription profiles of two
similarly cultured clinical isolates, MG 2300 and MG 2341
[24], under normal growth conditions. Array profiling of
these two cultures showed 13 genes that were significantly
up-regulated in MG 2300 compared to MG 2341 under
similar conditions (Fig. 3). Additionally, 27 significantly
down-regulated genes were identified in the MG 2300
culture compared to that of cultures containing isolate MG
2341.
Guinea pig array (gpArray) Due to its similarity to
humans, the guinea pig is often used to study human
infection and disease but currently suffers from a dearth of
associated immunologic reagents [25, 26]. To increase our
understanding of the immune response in these animals, we
utilized the flexibility of our platform to develop an array
capable of characterizing transcription changes in the
guinea pig. First-round primer design success rates for the
gpArray were 73 % with an associated 50 % success rate
for primer re-design, consistent with the greater complexity
of this genome compared to that of MG. Supplementary
Table S2 provides a summary of primer pair sequences and
associated Tms for the gpArray. Final array assessment was
conducted using guinea pig splenic cells cultured with
phorbol myristate acetate (PMA) plus ionomycin, an
immunostimulatory cocktail known to activate lymphocyte
proliferation and cytokine production. These samples were
studied for known shifts in transcription levels associated
with PMA/ionomycin stimulation.
We first compared gpArray data from 2 sets of duplicate
cultures of unstimulated splenocytes (1 9 106 cells/sam-
ple). A scatter plot (Fig. 4a) of this comparison showed
that no genes were up- or down-regulated more than 3-fold,
indicating that there were no meaningful differences in
transcription between these unstimulated samples. This
method also helped to establish the level of biologic and
technical noise in the PCR array. Comparison of array data
from stimulated splenocytes with the untreated control
values identified a number of genes that were differentially
expressed (Fig. 4b). When these results were statistically
analyzed, transcription levels of 15 genes were signifi-
cantly up-regulated and the transcription levels of an
additional 55 genes were significantly down-regulated
(Fig. 4c).
Confirmation of Identified Differential Gene
Expression
Sampling error and limits of detection can be serious
confounders for generalized array approaches. To address
these concerns, we utilized subsequent qPCR that included
10-fold dilution series of cloned amplimers from the
gpArray as standard curves. Single target qPCR allowed
Fig. 3 Comparisons between MG 2300 and MG 2341 showed
significant transcription level changes in 42 % of genes evaluated.
A plot comparing MG 2300 to MG 2341 showed that significant up-
regulation was detected for 13 genes (upper right quadrant).
Additionally, 27 genes were significantly down-regulated (upper left
quadrant). The gray rectangle indicates a 3-fold up- or down-
regulation. Approximately, 58 % of observed gene transcription
levels were found to fall within this range and were considered
unchanged. Selected genes were evaluated by qPCR, and both their
magnitude and direction of change were in agreement with the data
obtained from the array. The dotted line indicates a P value of 0.05
178 Mol Biotechnol (2015) 57:172–183
123
for larger sample size with increased statistical power to
confirm array, indicated shifts in the transcriptome of the
stimulated cell population. To establish this method and
effectively define confidence in meaningful array-based
differences, we selected qPCR targets representing the
highest up- and down-regulated differences as well as
differences representing mid- and minimally different fold
changes established in the arrays. Most of these targets
were deemed as significantly different in treated guinea pig
splenocytes.
Initial evaluation of the array results suggested ±3-fold
change would likely be meaningful but in pilot studies that
were intentionally underpowered, we discovered ±5-fold
to be more accurate. Comparison of the array and qPCR
data (Table 1) confirmed that all fold changes[5-fold were
concordant and significant comparing triplicate stimulated
samples to unstimulated controls (P \ 0.05). Of eight tar-
gets tested by qPCR with \5-fold difference indicated by
the array, 2 matched both direction and P value, 3 matched
direction only, and the remaining 3 were discordant for
both direction and significance (Fig. 4d). gpArray results
were found to be B5-fold change and therefore should be
confirmed by an alternative method. Importantly, all values
of [5-fold change are expected to be solidly concordant.
Discussion
The work described here illustrates the utility of our array
platform by providing two new resources for the evaluation
of transcriptional profiling for organisms that currently
suffer from a lack of commercially available assays. By
Fig. 4 Initial validation of the gpArray using guinea pig splenocytes
treated with medium only for 24 h (unstimulated) or PMA/ionomycin
(stimulated). Both (a) and (b). The solid line indicates baseline
expression; the dotted lines indicated 3-fold up or down expression
differences. a Replicates of unstimulated splenocytes showed no
differences validating the reproducibility of the array and establishing
the level of biological and technical noise. b When stimulated
splenocytes were compared to unstimulated samples, 16 % of genes
were found to be up-regulated, 60 % were down-regulated, and the
remaining genes showed no change. Both (c) and (d). The dotted line
indicates P value of 0.05. The light gray rectangle indicates a 3-fold
up or down change in expression levels. Gene transcription levels
within this range were considered unchanged. c Statistical signif-
icance of expression level differences from stimulated splenocytes
compared to unstimulated; 15 genes were significantly up-regulated
(upper right quadrant) and 55 were significantly down-regulated
(upper left quadrant). d qPCR results were concordant for direction of
change and P value for 54 % of genes evaluated (indicated by Black
filled star). Genes that were discordant with respect to direction,
P value or both were found within a 5-fold up- or down-regulation
and are denoted by (9). The dark gray rectangles indicate ±5-fold
change in expression levels with all genes that showed [5-fold
change corresponding to 100 % concordance with array data as
confirmed by qPCR
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utilizing the reliability of SYBR green-based chemistries
[27], we have developed a cost efficient, highly specific,
and reproducible methodology that can be adapted to any
target species for which whole or partial annotation of its
genome is available. The costs for the development of an
array are based upon several of the parameters we detail in
our method. Specifically, we estimated, on average, each
primer pair evaluation, including the cost of the primers
and PCR mix, was $32USD. Given the reported success
rate of designed primers, the cost of development and
validation of 96 compatible gene targets was under
$4,000USD. Once established, a 96 target array costs
$125USD/sample.
Our enhanced array system builds on previous primer
design and PCR parameters [12] to create a system com-
patible with standard molecular biology laboratories. Our
array platform can accommodate any number of genes
spanning multiple 96-well plates, making it feasible to
screen one sample across many genes or narrowing the
focus to evaluate only a few important genes using a ‘‘mini
array.’’ In this manner, multiple samples may be assayed
per plate, reducing costs while increasing throughput.
Thus, the platform is an ideal screening tool for detecting
transcription changes from individual or biologically
pooled samples to identify relevant differentially expressed
genes for subsequent evaluations. Additionally, the targets
included on each array can be converted easily to specific
sensitive qPCR assays using the primer sets already
incorporated on the platform. Such assays enable efficient
confirmation of the transcriptional changes detected by an
array for many individual samples. Finally, our approach
allows for the construction of a secondary array using only
those genes identified and confirmed by qPCRs, further
reducing overall costs and increasing the efficiency of array
screens.
There has been intense development in the area of
transcriptomics and associated technologies in recent years
[5], resulting in several options for gene expression ana-
lysis. RNA-seq can provide de novo evaluation of gene
expression in the absence of a reference genome [5],
making this an attractive option for researchers working
with an uncommon research species. However, this tech-
nology can be cost-prohibitive (*$250–3,000USD/sam-
ple) and requires a multi-step sample preparation that can
introduce unwanted bias into the results [7, 8]. In contrast,
PCR arrays are relatively inexpensive on a per sample basis
and can provide a more user-friendly approach to tran-
scription analysis. Unfortunately, while many signaling
pathways and disease states may be interrogated using
commercially available PCR arrays, the limited number of
target species prevents study of many important animal
models. Custom arrays may be requested, however there is
an associated lag time for their development that, coupled
with increased costs, lessen their appeal. The optimized
platform we have developed addresses these issues. Addi-
tionally, our methodology costs only $125USD/sample and
provides an alternative to other transcription assessments,
making it a more cost-effective and reproducible means of
approaching expression analysis for non-commercially
available species or signaling pathways. The array method
also provides for the opportunity to combine targets from
host and pathogen assemblies to coincidentally evaluate
two target species in one assay further enhancing
applicability.
Initial development of the array platform was driven by
our research into the emergence of MG as a sexually
transmitted pathogen [28, 29]. With the availability of
commercial reagents lacking for such an under-studied
organism, our goal was to provide an important tool for
understanding the transcriptome of this bacterium. Thus,
the MG array was developed to include individual genes
that are crucial to motility [30, 31], important in regulating
responses to environmental changes [32], and other
potential pathogenicity cues [33].
Utilizing the MG array, we investigated the variability
in gene transcription between different clinical isolates to
identify genes important to survival or adaptation to the
host environment. Screening detected transcriptional
changes that could be associated with drug resistance or
immune evasion. These observations resulted in a more
refined list of gene targets and the flexibility of our plat-
form provided the ability to easily re-configure a more
specific focused version of the MG array. This refined array
Table 1 qPCR validation of expression level changes from PMA/














IFNc 522.5 : Y 2.3 : Y
TLR-3 89.9 ; Y 1.4 ; Y
CD8a 15.4 ; Y 1.1 ; Y
CXCL10 12.8 : Y 1.6 : Y
OX40L 6.5 : Y 4.7 : Y
CD107b 4.7 ; Y 1.0 ; N
CD107a 4.4 ; Y 1.0 ; N
IL-21 3.9 : Y 1.8 : Y
B2 M 3.0 ; N 1.0 ; N
IFNAR1 2.3 : N 1.2 : Y
CXCR3 2.1 ; Y 1.3 : Y
TGFb 1.3 ; N 1.2 : Y
CD28 1.2 ; N 1.0 : N
Y: Yes, indicates a P value\0.05; N: No, indicates a P value[0.05;
:: indicates up-regulation; ;: indicates down-regulation
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will be used to identify new targets for therapeutic inter-
ventions and vaccine development.
As evidence of success with a more complex genome,
we developed an array for the guinea pig because it is an
excellent model for the study of infectious diseases [26,
34–37]. The guinea pig boasts immune and pathophysio-
logic similarities to humans that make it a preferred animal
for studying disease pathogenesis [38–40] and for evalu-
ating new vaccines [41, 42]. Despite the value of this small
animal model, full utilization of possible outcomes has
been hampered by a lack of commercially available
immunological assays. Independent researchers have
attempted to overcome these limitations, however the
resulting assays are often specific for only a single target
[25, 43, 44], restricting their utility to a smaller subset of
research applications.
Using the validated gpArray, pilot studies were com-
pleted to compare PMA/ionomycin-stimulated splenocytes
to unstimulated cells to identify changes in expression
levels associated with this non-specific immune activator
cocktail. This approach also helped to validate the sensi-
tivity of the gpArray providing defined cutoffs for mean-
ingful differences identified by the array. As expected, the
expression levels of interferon gamma (IFNc) increased
significantly compared to unstimulated controls. Not sur-
prisingly, additional interferon-stimulated genes (CXCL10
and CXCL11) were also found to be up-regulated along
with several interferon-induced lymphocyte activation
markers (CD69 and CD223). These results were in agree-
ment with known lymphocyte activation [45–47] and
confirmed that the gpArray could detect transcriptional
changes and could be useful as a screening tool.
The changes in expression levels that were observed
were confirmed by subsequent single target qPCR to vali-
date initial array results. The qPCR of selected targets
evaluated both large and small fold changes in up- and
down-regulated genes, and showed that transcription level
changes of ±3-fold were less meaningful than suggested by
initial array evaluations. Importantly, qPCR evaluations
showed 100 % concordance for expression changes of[5-
fold and indicated that changes \5-fold should be con-
firmed by alternate approaches or increased sample size.
Single target qPCR adapted from the existing primers on
the array proved an efficient and straightforward means of
addressing both statistical confirmation and increased
numbers of samples analyzed in cost-effective fashion.
Collectively, the presented data showed that our array
development platform was a reproducible and highly
adaptable resource for examining changes at the tran-
scriptional level in disparate organisms that lack optimal
assays for research. Importantly, the system can be used
with only partial genomic sequence from pathogens and
commensal organisms that are not yet cultured in a
laboratory as well as from more complex species currently
lacking a fully annotated genome. To our knowledge, the
MG array created by our method represents the first
resource for evaluating large-scale expression level chan-
ges in this emerging, sexually transmitted pathogen.
Additionally, while microarray technologies have been
used to study the guinea pig previously [48, 49], restric-
tions inherent to these technologies (e.g., increased costs
and diminished throughput that can reduce statistical
power) can be overcome using RT-PCR arrays. With real-
time PCR instruments increasingly common in research
laboratories, we believe RT-PCR arrays to be more
approachable and easily adopted by scientists studying
emerging organisms or species lacking available assays. In
addition, this developmental platform has the potential to
create tools to study multiple organisms present in a single
sample, i.e., pathogen in the context of host, providing a
simple and accurate new screening tool for gene expression
analysis.
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